Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502378 · ClinicalTrials.gov registry record · Phase 4
Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency
A Phase 4 study, sponsored by University of South Florida.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT07502378 is a Phase 4 study that is actively recruiting participants, run by University of South Florida. The registered enrollment target is 50 participants.
The verdict
NCT07502378, a Phase 4 study, is actively recruiting participants, sponsored by University of South Florida.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.
Interventions
- DRUG Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period.
- OTHER Alternative would be patient exiting the trial and starting on tears or other standard of care.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07502378
The ClinicalTrials.gov registry entry for NCT07502378 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period. is the first listed.
NCT07502378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07502378 about?
NCT07502378 is a clinical study titled "Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency". STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.
What is the current status of trial NCT07502378?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2026-03-27. Estimated completion is 2027-08-31.
What interventions are being tested in trial NCT07502378?
The interventions under investigation include: Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period. (DRUG), Alternative would be patient exiting the trial and starting on tears or other standard of care. (OTHER).
Who is sponsoring clinical trial NCT07502378?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.